Cannabis Added to Standard Pain Medications Did Not Reach Clinically Meaningful Pain Relief in Brachial Plexus Injury

A rigorous small crossover trial found that sublingual cannabis oil produced a statistically significant but clinically insufficient pain reduction in patients with traumatic brachial plexus injury, while sleep quality improved modestly, offering one of the clearest demonstrations of why the distinction between statistical significance and clinical importance matters in cannabinoid pain research.

Why This Matters

Traumatic brachial plexus injury produces some of the most treatment-resistant neuropathic pain in clinical medicine, and patients who fail standard triple-analgesic regimens have few remaining options. Cannabis-based medicines have generated substantial patient demand in this space, driven partly by preclinical evidence of cannabinoid modulation of neuropathic signaling. This trial matters because it is only the second randomized controlled trial ever conducted on cannabis for this specific population, and its negative primary finding, anchored to a pre-specified clinically meaningful threshold rather than p-values alone, provides the strongest evidence to date against routine addition of cannabis to standard analgesics for this condition.

Clinical Summary

Neuropathic pain following traumatic brachial plexus injury remains notoriously difficult to manage, even with multimodal pharmacotherapy. Researchers at Lerdsin General Hospital in Bangkok conducted a triple-blind, two-period crossover RCT, published as Level 1 therapeutic evidence, to determine whether adding sublingual cannabis oil to a background regimen of tramadol, gabapentin, and amitriptyline could produce clinically meaningful pain relief. The mechanistic rationale rests on cannabinoid receptor modulation of central and peripheral nociceptive pathways, with CB1 and CB2 receptors expressed in regions involved in neuropathic pain processing. Patients were highly selected: only about 20% of 147 screened individuals met eligibility, requiring concurrent failure on all three background analgesics at minimum therapeutic doses.

The cannabis intervention reduced pain VAS scores by a mean of 1 point more than placebo (99% CI -0.03 to 2.1; p = 0.01), a statistically significant result that nonetheless fell below the pre-specified minimum clinically important difference of 2 points. The DN4 neuropathic pain classification was unchanged between groups. Sleep quality, a secondary outcome, improved by 1.5 points on VAS favoring cannabis (99% CI 0.7 to 2.4; p < 0.001). Adverse events were limited to mild dizziness in 4 of 28 patients. Key limitations include the small sample size (28 analyzed), the short 10-day treatment period, single-center enrollment, and the possibility that the 14-day washout was insufficient for complete cannabinoid metabolite clearance. The authors concluded that cannabis-based medicine should not be added routinely to standard pain treatment for this population and called for larger, longer trials.

Dr. Caplan’s Take

This study does something important that too many cannabis trials fail to do: it defines success before looking at results and then honestly reports that the intervention did not meet the bar. The 1-point pain reduction is real in a statistical sense, but for patients living with severe, refractory neuropathic pain, it falls short of what they would notice or value. Patients with brachial plexus injuries ask me about cannabis regularly, and this study equips me to give a more honest answer than “we don’t know.” We now have Level 1 evidence suggesting the addition of sublingual cannabis oil to a robust analgesic backbone does not produce clinically important pain relief over 10 days.

In practice, I do not recommend cannabis as a primary add-on analgesic for this population based on current evidence. However, the sleep quality finding is intriguing and worth discussing with patients whose pain disrupts sleep, provided expectations are managed carefully. I continue to optimize standard multimodal regimens first and consider cannabis only within a shared decision-making framework where patients understand the evidence gap, and I monitor closely for any drug interactions with their existing medications.

Clinical Perspective

This trial sits at an early but critical point in the research arc for cannabis in brachial plexus injury pain. It confirms that sublingual cannabis can produce a modest analgesic signal in this population but demonstrates that the magnitude falls below clinical relevance as conventionally defined. The sleep quality improvement is the most promising secondary signal, though it was measured with a simple VAS rather than validated sleep instruments such as the Pittsburgh Sleep Quality Index, limiting interpretive weight. Clinicians should not extrapolate these findings to other neuropathic pain populations, different cannabis formulations, or longer treatment durations. The evidence does not support recommending cannabis addition for pain control in this group.

From a pharmacological standpoint, the intervention was capped at fewer than 30 mg THC per day delivered sublingually, a relatively low dose that may not capture the full dose-response relationship. Clinicians should also note the mandatory background of tramadol, gabapentin, and amitriptyline, all of which carry CNS-depressant and serotonergic interaction potential with cannabinoids. The dizziness reported in 14% of patients, while mild, likely reflects additive sedation. The most actionable recommendation now is to ensure that patients inquiring about cannabis for brachial plexus injury pain are informed that the best available RCT evidence does not support clinically meaningful pain improvement, while acknowledging the possibility of modest sleep benefits that require further validation.

Study at a Glance

Study Type

Triple-blind, two-period crossover randomized controlled trial with 14-day washout

Population

Adults with traumatic brachial plexus injury and refractory neuropathic pain on triple-analgesic therapy (n = 28 analyzed)

Intervention

Sublingual cannabis oil titrated to 5 drops four times daily (<30 mg THC/day) for 10 days

Comparator

Identical placebo sublingual oil for 10 days

Primary Outcomes

Pain VAS (0 to 10) with pre-specified MCID of 2 points; secondary outcomes included DN4 neuropathic pain classification and sleep quality VAS

Sample Size

147 screened, 30 enrolled, 28 analyzed

Journal

Published as Level 1 therapeutic evidence (journal not specified in source data)

Year

Enrollment January 2020 to January 2022

DOI or PMID

Pre-registered in Thai Clinical Trials Registry (specific identifier not provided in source data)

Funding Source

Thai Ministry of Public Health; no commercial funding

What Kind of Evidence Is This

This is a prospective, triple-blinded, placebo-controlled, two-period crossover randomized controlled trial reported according to CONSORT crossover extension guidelines and classified as Level 1 therapeutic evidence. As an RCT, it supports causal inference within its design parameters. The most important inference constraint is the small analyzed sample of 28 patients, which limits precision for secondary outcomes and makes subgroup analysis unreliable, and the 10-day treatment window, which may be too short to detect delayed or cumulative analgesic effects of cannabinoids.

How This Fits With the Broader Literature

This trial is only the second RCT to examine cannabis for traumatic brachial plexus injury pain, making it a significant addition to an extremely thin evidence base. Its negative primary finding aligns with the broader pattern in cannabinoid analgesia research, where statistically significant but clinically modest pain reductions are common across neuropathic pain trials. Systematic reviews of cannabis for neuropathic pain generally report number-needed-to-treat figures in the range of 5 to 10, with effect sizes that frequently hover near or below accepted MCIDs. The sleep quality finding parallels observations from other cannabinoid trials showing more consistent effects on sleep than on pain itself, though the use of unvalidated sleep measures in this and many prior studies limits firm conclusions.

What distinguishes this trial is the authors’ commitment to interpreting results through the MCID lens rather than celebrating p-value significance, a methodological standard that the broader cannabis research field would benefit from adopting more consistently.

Common Misreadings

The most likely overinterpretation is to cite the statistically significant p-value of 0.01 for pain reduction as evidence that cannabis “works” for brachial plexus injury pain. This reading ignores the study’s own analytic framework, which pre-specified that a 2-point VAS improvement constituted the threshold of clinical importance. The observed 1-point mean difference, with a 99% confidence interval whose lower bound barely crosses zero at -0.03, could plausibly represent a negligible effect. Equally, it would be a misreading to dismiss the sleep quality finding entirely; while it is a secondary outcome and was measured with a simple VAS, the confidence interval is entirely above zero, and the signal is strong enough to justify dedicated investigation with validated sleep instruments in future trials.

Bottom Line

This well-designed crossover RCT provides the clearest evidence to date that adding sublingual cannabis oil to standard triple-analgesic therapy does not produce clinically important pain relief in traumatic brachial plexus injury patients over 10 days. The sleep quality improvement is the most promising finding but remains a secondary outcome requiring replication with validated instruments. Clinicians should not recommend cannabis addition for pain in this population based on current evidence, though shared decision-making about sleep-related benefits may be reasonable when expectations are carefully managed.

References

1. Lerdsin General Hospital investigators. Triple-blind, two-period crossover RCT of sublingual cannabis-based medicine for traumatic brachial plexus injury pain. Pre-registered in the Thai Clinical Trials Registry. Funded by the Thai Ministry of Public Health. Enrollment January 2020 to January 2022.